Analyzing Organigram Global (NASDAQ:OGI) and Owlet (NYSE:OWLT)

Owlet (NYSE:OWLT) and Organigram Global (NASDAQ:OGI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, risk, earnings and profitability.

Risk & Volatility

Owlet has a beta of 1.9, meaning that its share price is 90% more volatile than the S&P 500. Comparatively, Organigram Global has a beta of 1.49, meaning that its share price is 49% more volatile than the S&P 500.

Earnings & Valuation

This table compares Owlet and Organigram Global”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Owlet	$105.70 million	1.26	-$39.68 million	($0.75)	-6.07
Organigram Global	$185.07 million	0.81	-$17.70 million	$0.46	2.30

Organigram Global has higher revenue and earnings than Owlet. Owlet is trading at a lower price-to-earnings ratio than Organigram Global, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

72.6% of Owlet shares are owned by institutional investors. Comparatively, 34.6% of Organigram Global shares are owned by institutional investors. 36.2% of Owlet shares are owned by insiders. Comparatively, 0.1% of Organigram Global shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Owlet and Organigram Global’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Owlet	-8.61%	-601.24%	-15.96%
Organigram Global	28.14%	-13.39%	-8.67%

Analyst Ratings

This is a summary of current ratings and recommmendations for Owlet and Organigram Global, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Owlet	1	1	3	0	2.40
Organigram Global	1	0	2	0	2.33

Owlet presently has a consensus target price of $15.00, indicating a potential upside of 229.60%. Given Owlet’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Owlet is more favorable than Organigram Global.

About Owlet

Owlet, Inc. provides digital parenting solutions in the United States and internationally. The company's platform focuses on giving real-time data and insights to parents. It offers Dream Sock, a wearable infant health monitor equipped with pulse oximetry technology to track vitals signs, such as pulse rate, oxygen, activity, and sleep patterns; BabySat which is intended for infants with heightened health risk; Owlet Cam, a monitoring device in smartphones that offers video and audio, predictive sleep insights, and cry detections; and accessories, including Owlet Sleeper, as well as Duo and Dream Duo that combines Smart Sock with the Owlet Cam. The company was founded in 2012 and is headquartered in Lehi, Utah.

About Organigram Global

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.